Cardinal Health May Alter Syncor Deal
From Times Staff and Wire Reports
Drug wholesaler Cardinal Health Inc. has started talks about possibly revising its $1.1-billion deal for Syncor International Corp., the Woodland Hills-based nuclear pharmacy services company that is investigating whether its subsidiaries made improper payments to overseas customers.
Based on its review so far, Syncor believes it can satisfy conditions of the acquisition, the firms said in a joint statement. Cardinal said it had not concluded whether the merger could be completed.
Cardinal fell $2.95 to $62.05 on the NYSE. Syncor closed up $1.20 to $25.40 on Nasdaq.
